{
    "info": {
        "nct_id": "NCT03009240",
        "official_title": "A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia",
        "inclusion_criteria": "* Patients diagnosed with acute myeloid leukemia (AML) by World Health Organization (WHO) classification, meeting one of following criteria:\n\n  * Age 60 or older, newly diagnosed, untreated, who are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines\n  * Age 60 or older with relapsed or refractory disease\n  * Younger adult patients with previously untreated high-risk disease (complex karyotype, inv[3] or t[3;3], t[6;9], monosomal karyotype, therapy-related and secondary disease) that are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines and/or allogeneic stem cell transplantation\n  * Younger patients with refractory/relapsed AML who are otherwise not candidates for allogeneic stem cell transplantation\n  * Patients with extramedullary disease who meet one of the above criteria may be included\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Patients with co-morbid medical illness, life expectancy attributed to this must be greater than 6 months\n* The effects of pevonedistat and decitabine on the developing fetus is unknown; for this reason, women of child bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for 4 months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n* Female patients must be:\n\n  * Postmenopausal for at least 1 year before the screening visit, OR\n  * Surgically sterile, OR\n  * If they are of childbearing potential\n\n    * Agree to practice 1 highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), OR\n  * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception)\n* Male patients, even if surgically sterilized (i.e., status post-vasectomy) must:\n\n  * Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug (female and male condoms should not be used together), or\n  * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception)\n* Creatinine < 1.5 X institutional upper limit of normal\n* OR creatinine clearance >= 60 mL/min for patients with creatinine levels above 1.5 X institutional upper limit of normal\n* Cardiac ejection fraction >= 50%\n* Albumin > 2.7 g/dL\n* Total bilirubin =< institutional upper limit of normal (ULN) (except in patients with Gilbert's syndrome; patients with Gilbert's syndrome may enroll if direct bilirubin is =< 1.5 x ULN\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ULN unless higher levels are related to leukemic infiltration\n* Hemoglobin > 8 g/dL; patients may be transfused to receive this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed\n* All subjects must have the ability to understand and the willingness to sign a written informed consent\n* The following patients are allowed:\n\n  * Patients may have been treated for AML or antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or decitabine\n  * Any prior chemo therapy must have been completed >= 2 weeks prior to day 1 of study treatment and the participant must have recovered to eligibility levels from prior toxicity\n  * There is no limit for prior chemo regimens\n  * Patients may have received hematopoietic stem cell transplantation for AML or other diseases\n  * Hydroxyurea is allowed prior to day 1 of study treatment for count control and during cycle 1; the use of hydroxyurea is not allowed beyond completion of cycle 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat or decitabine\n* Patients have received prior chemotherapy or radiation for AML < two weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered\n* Females who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drug\n* Patients with additional (other than AML) active malignancies, other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin; patients are not considered to have a \"currently active\" malignancy if they have completed therapy for a prior malignancy and disease free from prior malignancies for > 2 years\n* Life-threatening illness unrelated to cancer\n* Known cardiopulmonary disease defined as one of the following:\n\n  * Unstable angina\n  * Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)\n  * Cardiomyopathy or history of ischemic heart disease\n  * Arrhythmia (eg, history of polymorphic ventricular fibrillation or torsade de pointes); permanent atrial fibrillation (a fib) defined as a fib >= 6 months; persistent a fib defined as sustained a fib lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening; however, patients with < grade 3 atrial fibrillation (a fib) for a period of at least 6 months may enroll; grade 3 a fib is symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation; patients with paroxysmal a fib are permitted to enroll\n  * Implantable cardioverter defibrillator\n  * Congestive heart failure (New York Heart Association [NYHA] class III or IV; or class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening),\n  * Myocardial infarction and/or revascularization (eg, coronary artery bypass graft, stent) within 6 months of first dose of study drug\n  * Patients who had ischemic heart disease who have had ACS, MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll\n  * Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing)\n  * Pulmonary hypertension\n* Patients with uncontrolled coagulopathy or bleeding disorder\n* Prolonged rate corrected QT (QTc) interval of > 500 msec, calculated according to institutional guidelines\n* Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography\n* Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis\n* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures\n* Treatment with any investigational products within 14 days before the first dose of any study drug\n* Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, septicemia, or methicillin resistant Staphylococcus aureus infection\n* Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period\n* Known central nervous system (CNS) involvement\n* Known human immunodeficiency virus (HIV) seropositive\n* Known hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection; Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load; patients who have positive hepatitic C antibody may be included if they have an undetectable hepatitis C viral load\n* Known hepatic cirrhosis or severe pre-existing hepatic impairment\n* Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea\n* White blood cell (WBC) > 50,000/mcL\n* Treatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study (CYP3A4/5 inducers)\n* Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)\n* Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)\n* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* There is no limit for prior chemo regimens",
            "criterions": [
                {
                    "exact_snippets": "no limit for prior chemo regimens",
                    "criterion": "number of prior chemotherapy regimens",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": "no limit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients diagnosed with acute myeloid leukemia (AML) by World Health Organization (WHO) classification, meeting one of following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Patients diagnosed with acute myeloid leukemia (AML) by World Health Organization (WHO) classification",
                    "criterion": "acute myeloid leukemia diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "acute myeloid leukemia (AML)"
                        },
                        {
                            "requirement_type": "classification_system",
                            "expected_value": "World Health Organization (WHO)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine < 1.5 X institutional upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Creatinine < 1.5 X institutional upper limit of normal",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception)",
            "criterions": [
                {
                    "exact_snippets": "Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject",
                    "criterion": "sexual abstinence",
                    "requirements": [
                        {
                            "requirement_type": "agreement to practice",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consistency with lifestyle",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "acceptable methods",
                            "expected_value": "true abstinence only"
                        },
                        {
                            "requirement_type": "unacceptable methods",
                            "expected_value": [
                                "periodic abstinence",
                                "withdrawal",
                                "spermicides only",
                                "lactational amenorrhea"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age 60 or older with relapsed or refractory disease",
            "criterions": [
                {
                    "exact_snippets": "Age 60 or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Younger patients with refractory/relapsed AML who are otherwise not candidates for allogeneic stem cell transplantation",
            "criterions": [
                {
                    "exact_snippets": "Younger patients",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age group",
                            "expected_value": "younger"
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory/relapsed AML",
                    "criterion": "acute myeloid leukemia (AML) status",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "refractory",
                                "relapsed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not candidates for allogeneic stem cell transplantation",
                    "criterion": "eligibility for allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may have been treated for AML or antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or decitabine",
            "criterions": [
                {
                    "exact_snippets": "Patients may have been treated for AML or antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or decitabine",
                    "criterion": "prior treatment for AML or antecedent hematologic disorder",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "myeloid growth factors",
                                "recombinant erythropoietin",
                                "thalidomide",
                                "lenalidomide",
                                "5-azacitidine",
                                "decitabine"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception)",
            "criterions": [
                {
                    "exact_snippets": "Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject",
                    "criterion": "true abstinence",
                    "requirements": [
                        {
                            "requirement_type": "agreement to practice",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consistency with lifestyle",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "acceptable methods",
                            "expected_value": "true abstinence"
                        },
                        {
                            "requirement_type": "unacceptable methods",
                            "expected_value": [
                                "periodic abstinence",
                                "withdrawal",
                                "spermicides only",
                                "lactational amenorrhea"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients must be:",
            "criterions": [
                {
                    "exact_snippets": "Female patients must be",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If they are of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "If they are of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may have received hematopoietic stem cell transplantation for AML or other diseases",
            "criterions": [
                {
                    "exact_snippets": "Patients may have received hematopoietic stem cell transplantation for AML or other diseases",
                    "criterion": "hematopoietic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for AML or other diseases",
                    "criterion": "prior disease indication for transplantation",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "AML",
                                "other diseases"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Postmenopausal for at least 1 year before the screening visit, OR",
            "criterions": [
                {
                    "exact_snippets": "Postmenopausal for at least 1 year before the screening visit",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with extramedullary disease who meet one of the above criteria may be included",
            "criterions": [
                {
                    "exact_snippets": "Patients with extramedullary disease",
                    "criterion": "extramedullary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "who meet one of the above criteria",
                    "criterion": "one of the above criteria",
                    "requirements": [
                        {
                            "requirement_type": "satisfaction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug (female and male condoms should not be used together), or",
            "criterions": [
                {
                    "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception type",
                            "expected_value": "effective barrier contraception"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "entire study treatment period and through 6 months after the last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "female and male condoms should not be used together",
                    "criterion": "contraception method combination",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": "female and male condoms used together"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The effects of pevonedistat and decitabine on the developing fetus is unknown; for this reason, women of child bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for 4 months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",
            "criterions": [
                {
                    "exact_snippets": "women of child bearing potential ... must agree to use effective contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for 4 months following duration of study participation",
                    "criterion": "contraception use (women of child bearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "prior to study entry"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months following duration of study participation"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "men must agree to use effective contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for 4 months following duration of study participation",
                    "criterion": "contraception use (men)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "prior to study entry"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months following duration of study participation"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Surgically sterile, OR",
            "criterions": [
                {
                    "exact_snippets": "Surgically sterile",
                    "criterion": "surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with co-morbid medical illness, life expectancy attributed to this must be greater than 6 months",
            "criterions": [
                {
                    "exact_snippets": "co-morbid medical illness, life expectancy attributed to this must be greater than 6 months",
                    "criterion": "life expectancy attributed to co-morbid medical illness",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 8 g/dL; patients may be transfused to receive this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients may be transfused to receive this value",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "transfusion allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "elevated indirect bilirubin due to post-transfusion hemolysis is allowed",
                    "criterion": "indirect bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "elevation due to post-transfusion hemolysis allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac ejection fraction >= 50%",
            "criterions": [
                {
                    "exact_snippets": "Cardiac ejection fraction >= 50%",
                    "criterion": "cardiac ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ULN unless higher levels are related to leukemic infiltration",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... =< 2.5 ULN unless higher levels are related to leukemic infiltration",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless higher levels are related to leukemic infiltration"
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ... =< 2.5 ULN unless higher levels are related to leukemic infiltration",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless higher levels are related to leukemic infiltration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male patients, even if surgically sterilized (i.e., status post-vasectomy) must:",
            "criterions": [
                {
                    "exact_snippets": "Male patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "even if surgically sterilized (i.e., status post-vasectomy)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "status post-vasectomy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior chemo therapy must have been completed >= 2 weeks prior to day 1 of study treatment and the participant must have recovered to eligibility levels from prior toxicity",
            "criterions": [
                {
                    "exact_snippets": "Any prior chemo therapy must have been completed >= 2 weeks prior to day 1 of study treatment",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "completion interval before study treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the participant must have recovered to eligibility levels from prior toxicity",
                    "criterion": "recovery from prior toxicity",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "recovered to eligibility levels"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hydroxyurea is allowed prior to day 1 of study treatment for count control and during cycle 1; the use of hydroxyurea is not allowed beyond completion of cycle 1",
            "criterions": [
                {
                    "exact_snippets": "Hydroxyurea is allowed prior to day 1 of study treatment for count control and during cycle 1; the use of hydroxyurea is not allowed beyond completion of cycle 1",
                    "criterion": "hydroxyurea use",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior to day 1 of study treatment",
                                "during cycle 1"
                            ]
                        },
                        {
                            "requirement_type": "prohibition_timing",
                            "expected_value": "beyond completion of cycle 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree to practice 1 highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), OR",
            "criterions": [
                {
                    "exact_snippets": "Agree to practice 1 highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug",
                    "criterion": "contraception method use",
                    "requirements": [
                        {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        },
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": [
                                "1 highly effective",
                                "1 additional effective (barrier)"
                            ]
                        },
                        {
                            "requirement_type": "simultaneous use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the time of signing the informed consent through 4 months after the last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "female and male condoms should not be used together",
                    "criterion": "contraception method combination",
                    "requirements": [
                        {
                            "requirement_type": "prohibited combination",
                            "expected_value": "female and male condoms together"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All subjects must have the ability to understand and the willingness to sign a written informed consent",
            "criterions": [
                {
                    "exact_snippets": "ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Younger adult patients with previously untreated high-risk disease (complex karyotype, inv[3] or t[3;3], t[6;9], monosomal karyotype, therapy-related and secondary disease) that are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines and/or allogeneic stem cell transplantation",
            "criterions": [
                {
                    "exact_snippets": "Younger adult patients",
                    "criterion": "age group",
                    "requirements": [
                        {
                            "requirement_type": "age group",
                            "expected_value": "younger adult"
                        }
                    ]
                },
                {
                    "exact_snippets": "previously untreated high-risk disease",
                    "criterion": "treatment history of high-risk disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "previously untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "complex karyotype",
                    "criterion": "complex karyotype",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inv[3] or t[3;3], t[6;9]",
                    "criterion": "specific chromosomal abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "inv[3]",
                                "t[3;3]",
                                "t[6;9]"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "monosomal karyotype",
                    "criterion": "monosomal karyotype",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "therapy-related and secondary disease",
                    "criterion": "disease etiology",
                    "requirements": [
                        {
                            "requirement_type": "etiology",
                            "expected_value": [
                                "therapy-related",
                                "secondary disease"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines and/or allogeneic stem cell transplantation",
                    "criterion": "eligibility for conventional induction chemotherapy and/or allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "willingness or candidacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age 60 or older, newly diagnosed, untreated, who are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines",
            "criterions": [
                {
                    "exact_snippets": "Age 60 or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "newly diagnosed",
                    "criterion": "diagnosis status",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated",
                    "criterion": "treatment status",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines",
                    "criterion": "eligibility for conventional induction chemotherapy with cytarabine/anthracyclines",
                    "requirements": [
                        {
                            "requirement_type": "willingness or candidacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< institutional upper limit of normal (ULN) (except in patients with Gilbert's syndrome; patients with Gilbert's syndrome may enroll if direct bilirubin is =< 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< institutional upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with Gilbert's syndrome may enroll if direct bilirubin is =< 1.5 x ULN",
                    "criterion": "direct bilirubin (in patients with Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* OR creatinine clearance >= 60 mL/min for patients with creatinine levels above 1.5 X institutional upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "creatinine clearance >= 60 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with creatinine levels above 1.5 X institutional upper limit of normal",
                    "criterion": "creatinine level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin > 2.7 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Albumin > 2.7 g/dL",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.7,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing)",
            "criterions": [
                {
                    "exact_snippets": "Moderate to severe aortic and/or mitral stenosis",
                    "criterion": "aortic stenosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Moderate to severe aortic and/or mitral stenosis",
                    "criterion": "mitral stenosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "other valvulopathy (ongoing)",
                    "criterion": "valvulopathy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis",
            "criterions": [
                {
                    "exact_snippets": "Known moderate to severe chronic obstructive pulmonary disease (COPD)",
                    "criterion": "chronic obstructive pulmonary disease (COPD)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "known",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary fibrosis",
                    "criterion": "pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hepatic cirrhosis or severe pre-existing hepatic impairment",
            "criterions": [
                {
                    "exact_snippets": "Known hepatic cirrhosis",
                    "criterion": "hepatic cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pre-existing hepatic impairment",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "pre-existence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 14 days before the first dose of any study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery before first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "scheduled surgery during study period",
                    "criterion": "scheduled surgery",
                    "requirements": [
                        {
                            "requirement_type": "occurrence during study period",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) < 50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by echocardiogram or radionuclide angiography",
                    "criterion": "assessment method for LVEF",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "echocardiogram",
                                "radionuclide angiography"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any investigational products within 14 days before the first dose of any study drug",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any investigational products within 14 days before the first dose of any study drug",
                    "criterion": "treatment with investigational products",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat or decitabine",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat or decitabine",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to pevonedistat or decitabine",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arrhythmia (eg, history of polymorphic ventricular fibrillation or torsade de pointes); permanent atrial fibrillation (a fib) defined as a fib >= 6 months; persistent a fib defined as sustained a fib lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening; however, patients with < grade 3 atrial fibrillation (a fib) for a period of at least 6 months may enroll; grade 3 a fib is symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation; patients with paroxysmal a fib are permitted to enroll",
            "criterions": [
                {
                    "exact_snippets": "Arrhythmia (eg, history of polymorphic ventricular fibrillation or torsade de pointes)",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "polymorphic ventricular fibrillation",
                                "torsade de pointes"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "permanent atrial fibrillation (a fib) defined as a fib >= 6 months",
                    "criterion": "permanent atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "persistent a fib defined as sustained a fib lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening",
                    "criterion": "persistent atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "cardioversion requirement",
                            "expected_value": "in the 4 weeks before screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with < grade 3 atrial fibrillation (a fib) for a period of at least 6 months may enroll",
                    "criterion": "atrial fibrillation grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 3 a fib is symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation",
                    "criterion": "grade 3 atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": [
                                "incompletely controlled medically",
                                "controlled with device",
                                "controlled with ablation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with paroxysmal a fib are permitted to enroll",
                    "criterion": "paroxysmal atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "enrollment permission",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known cardiopulmonary disease defined as one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Known cardiopulmonary disease",
                    "criterion": "cardiopulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pulmonary hypertension",
            "criterions": [
                {
                    "exact_snippets": "Pulmonary hypertension",
                    "criterion": "pulmonary hypertension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with additional (other than AML) active malignancies, other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin; patients are not considered to have a \"currently active\" malignancy if they have completed therapy for a prior malignancy and disease free from prior malignancies for > 2 years",
            "criterions": [
                {
                    "exact_snippets": "Patients with additional (other than AML) active malignancies",
                    "criterion": "active malignancies (other than AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin",
                    "criterion": "curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients are not considered to have a \"currently active\" malignancy if they have completed therapy for a prior malignancy and disease free from prior malignancies for > 2 years",
                    "criterion": "disease free from prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "duration disease free",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea",
            "criterions": [
                {
                    "exact_snippets": "Systemic antineoplastic therapy ... within 14 days before the first dose of any study drug",
                    "criterion": "systemic antineoplastic therapy for other malignant conditions",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy for other malignant conditions within 14 days before the first dose of any study drug",
                    "criterion": "radiotherapy for other malignant conditions",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for hydroxyurea",
                    "criterion": "hydroxyurea use",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prolonged rate corrected QT (QTc) interval of > 500 msec, calculated according to institutional guidelines",
            "criterions": [
                {
                    "exact_snippets": "Prolonged rate corrected QT (QTc) interval of > 500 msec",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)",
            "criterions": [
                {
                    "exact_snippets": "Male patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)",
                    "criterion": "intention to donate sperm",
                    "requirements": [
                        {
                            "requirement_type": "time period",
                            "expected_value": [
                                "during the course of this study",
                                "4 months after receiving their last dose of study drug(s)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic blood pressure > 180 mm Hg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 180,
                                "unit": "mm Hg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure > 95 mm Hg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 95,
                                "unit": "mm Hg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Implantable cardioverter defibrillator",
            "criterions": [
                {
                    "exact_snippets": "Implantable cardioverter defibrillator",
                    "criterion": "implantable cardioverter defibrillator",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure (New York Heart Association [NYHA] class III or IV; or class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening),",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure (New York Heart Association [NYHA] class III or IV",
                    "criterion": "congestive heart failure NYHA class",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening",
                    "criterion": "congestive heart failure NYHA class II with recent decompensation",
                    "requirements": [
                        {
                            "requirement_type": "recent decompensation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hospitalization or referral to a heart failure clinic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with the safety monitoring requirements of the study",
                    "criterion": "ability to comply with safety monitoring requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures",
                    "criterion": "serious medical or psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known central nervous system (CNS) involvement",
            "criterions": [
                {
                    "exact_snippets": "Known central nervous system (CNS) involvement",
                    "criterion": "central nervous system (CNS) involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, septicemia, or methicillin resistant Staphylococcus aureus infection",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe infectious disease",
                    "criterion": "infectious disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "meningitis",
                    "criterion": "meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "septicemia",
                    "criterion": "septicemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "methicillin resistant Staphylococcus aureus infection",
                    "criterion": "methicillin resistant Staphylococcus aureus infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)",
            "criterions": [
                {
                    "exact_snippets": "Female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)",
                    "criterion": "intention to donate eggs",
                    "requirements": [
                        {
                            "requirement_type": "time period",
                            "expected_value": [
                                "during the course of this study",
                                "4 months after receiving their last dose of study drug(s)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Females who are both lactating and breastfeeding",
                    "criterion": "lactation and breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive serum pregnancy test during the screening period",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the screening period"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive urine pregnancy test on day 1 before first dose of study drug",
                    "criterion": "urine pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "on day 1 before first dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection; Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load; patients who have positive hepatitic C antibody may be included if they have an undetectable hepatitis C viral load",
            "criterions": [
                {
                    "exact_snippets": "Known hepatitis B surface antigen seropositive",
                    "criterion": "hepatitis B surface antigen seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known or suspected active hepatitis C infection",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load",
                    "criterion": "hepatitis B core antibody with negative surface antigen and antibody",
                    "requirements": [
                        {
                            "requirement_type": "core antibody positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "surface antigen negativity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "surface antibody negativity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hepatitis B viral load",
                            "expected_value": "undetectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who have positive hepatitic C antibody may be included if they have an undetectable hepatitis C viral load",
                    "criterion": "hepatitis C antibody positivity",
                    "requirements": [
                        {
                            "requirement_type": "antibody positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hepatitis C viral load",
                            "expected_value": "undetectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known human immunodeficiency virus (HIV) seropositive",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus (HIV) seropositive",
                    "criterion": "HIV serostatus",
                    "requirements": [
                        {
                            "requirement_type": "seropositive",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction and/or revascularization (eg, coronary artery bypass graft, stent) within 6 months of first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction ... within 6 months of first dose of study drug",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "revascularization (eg, coronary artery bypass graft, stent) within 6 months of first dose of study drug",
                    "criterion": "revascularization procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life-threatening illness unrelated to cancer",
            "criterions": [
                {
                    "exact_snippets": "Life-threatening illness unrelated to cancer",
                    "criterion": "life-threatening illness unrelated to cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study (CYP3A4/5 inducers)",
            "criterions": [
                {
                    "exact_snippets": "Treatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug",
                    "criterion": "treatment with clinically significant metabolic enzyme inducers",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant metabolic enzyme inducers are not permitted during this study (CYP3A4/5 inducers)",
                    "criterion": "treatment with clinically significant metabolic enzyme inducers (CYP3A4/5 inducers) during study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White blood cell (WBC) > 50,000/mcL",
            "criterions": [
                {
                    "exact_snippets": "White blood cell (WBC) > 50,000/mcL",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiomyopathy or history of ischemic heart disease",
            "criterions": [
                {
                    "exact_snippets": "Cardiomyopathy",
                    "criterion": "cardiomyopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ischemic heart disease",
                    "criterion": "ischemic heart disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with uncontrolled coagulopathy or bleeding disorder",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled coagulopathy",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "bleeding disorder",
                    "criterion": "bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who had ischemic heart disease who have had ACS, MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll",
            "criterions": [
                {
                    "exact_snippets": "ischemic heart disease",
                    "criterion": "ischemic heart disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ACS, MI, and/or revascularization greater than 6 months before screening",
                    "criterion": "history of ACS, MI, and/or revascularization",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "event_occurred",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without cardiac symptoms",
                    "criterion": "cardiac symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients have received prior chemotherapy or radiation for AML < two weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered",
            "criterions": [
                {
                    "exact_snippets": "Patients have received prior chemotherapy or radiation for AML < two weeks before study enrollment",
                    "criterion": "prior chemotherapy or radiation for AML",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "those who have not recovered from the adverse events due to agents administered",
                    "criterion": "recovery from adverse events due to prior agents",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* The following patients are allowed:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}